Nicotinic receptor decreases in the frontal cortex and hippocampus are important mediators of cognitive impairment in both schizophrenia and Alzheimer's disease. Drug treatments for these diseases should take into account the impacts of compromised brain function on drug response. This study investigated the impact of compromised nicotinic receptor activity in the frontal cortex in rats on memory function. Since both Alzheimer's disease and schizophrenia can involve psychosis, antipsychotic drugs are often given. The impacts of antipsychotic drugs on cognitive function have been found to be quite variable. It is the hypothesis of this and previous studies that the cognitive effects of antispychotic drugs on cognitive function depend on the integrity of brain systems involved in cognition. Previously in studies of the hippocampus, we found that chronic inhibition of β2-containing nicotinic receptors with dihydro-β-erythrodine (DHβE) impaired working memory and that this effect was attenuated by the antipsychotic drug clozapine. In contrast, chronic hippocampal α7 nicotinic receptor blockade with methyllycaconitine (MLA) potentiated the clozapineinduced memory impairment which is seen in rats without compromised nicotinic receptor activity. The current study determined medial frontal cortical α7 and β2-containing nicotinic receptor involvement in memory and the interactions with antipsychotic drug therapy with clozapine. Chronic DHβE and MLA infusion effects and interactions with systemic clozapine were assessed in female rats tested for memory on the radial-arm maze. Antipsychotic drug interactions with chronic systemic nicotine were investigated because nicotinic procognitive treatment has been proposed. The same local infusion DHβE dose that impaired memory with hippocampal infusion did not impair memory when infused in the medial frontal cortex. Frontal DHβE infusion potentiated clozapine-induced memory impairment, whereas previously the memory impairment caused by hippocampal DHβE infusion was attenuated by clozapine. Frontal cortical MLA infusions at a dose that previously was found to potentiate the clozapine-induced memory impairment with hippocampal infusion had no significant effect when infused into the medial frontal cortex. The location and subtype of nicotinic receptor underactivity are critical determinates for clozapine effects on memory. Patients with hippocampal β2-containing nicotinic receptor loss may be well treated with clozapine therapy, while those with frontal cortical β2-containing receptor loss may have a potentiated memory impairment caused by clozapine.
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Introduction
Nicotinic acetylcholine receptors have been shown in a wide variety of studies in rodents, monkeys and humans to play crucial roles in memory function (Levin et al., 2006) . Nicotinic receptor expression decreases are seen in Alzheimer's disease (Kellar and Wonnacott, 1990; London et al., 1989; Perry et al., 1987; Schröder et al., 1991) and schizophrenia (Durany et al., 2000; Guan et al., 1999) , which are both diseases with memory impairment (Baddeley et al., 1991; Tollefson, 1996) . Nicotinic receptors are located in areas of the brain known to be critical substrates for memory processing including limbic system structures such as the hippocampus as well as the frontal cortex (Levin et al., 2006) . The specific roles of nicotinic receptor subtypes in each of these areas with memory function are now in the process of being discovered.
Nicotinic receptor losses in the hippocampus and frontal cortex are likely to underlie the cognitive decline in Alzheimer's disease (Kendziorra et al., 2006; London et al., 1989; Schröder et al., 1991) . The location of the greater amount of nicotinic receptor loss may be a critical determinant of the nature of the cognitive deficits and the nature of therapeutic drug response. With schizophrenia there are 
